A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)Pavlina Spiliopoulou, Sarah P. Blagden, Thomas W. Holmes et al.|Journal of Experimental & Clinical Cancer Research|2024Cited by 8
A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignanciesSarah P. Blagden, T.R. Jeffry Evans, Chrissie Butcher et al.|Annals of Oncology|2018Cited by 2